Literature DB >> 33553612

New insights into methotrexate accumulation in leukemia cells in vivo.

Elixabet Lopez-Lopez1, William E Evans2,3,4.   

Abstract

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time, folylpolyglutamate synthase mRNA expression, and MTX systemic clearance explain 42% of the variation in active MTXPGs accumulation in ALL cells in vivo, providing insights into mechanisms underlying interpatient differences in the antileukemic effects of HDMTX.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  (5-10): methotrexate; acute lymphoblastic leukemia; folate genes; molecular subtype; pharmacogenomics; pharmacokinetic

Year:  2021        PMID： 33553612      PMCID： PMC7849719          DOI： 10.1080/23723556.2020.1865086

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  7 in total

1.  Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.

Authors:  Elixabet Lopez-Lopez; Robert J Autry; Colton Smith; Wenjian Yang; Steven W Paugh; John C Panetta; Kristine R Crews; Erik J Bonten; Brandon Smart; Deqing Pei; J Robert McCorkle; Barthelemy Diouf; Kathryn G Roberts; Lei Shi; Stanley Pounds; Cheng Cheng; Charles G Mullighan; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

2.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors:  Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors:  Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

4.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

5.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

6.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 7.  The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.

Authors:  Jose J G Marin; Maria J Monte; Alba G Blazquez; Rocio I R Macias; Maria A Serrano; Oscar Briz
Journal:  Acta Pharmacol Sin       Date:  2013-12-09       Impact factor: 6.150
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.